肿瘤细胞去分化如何驱动免疫逃逸和对免疫治疗的抵抗。
How Tumor Cell Dedifferentiation Drives Immune Evasion and Resistance to Immunotherapy.
机构信息
Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Department of Cell and Developmental Biology, University of Pennsylvania, Philadelphia, Pennsylvania.
出版信息
Cancer Res. 2020 Oct 1;80(19):4037-4041. doi: 10.1158/0008-5472.CAN-20-1420. Epub 2020 Jun 18.
Abstract
Immunotherapy has revolutionized cancer treatment, yet most patients do not respond. While tumor antigens are needed for effective immunotherapy, a favorable tumor immune microenvironment is also critical. In this review, we discuss emerging evidence that tumor cells exploit cellular plasticity and dedifferentiation programs to avoid immune surveillance, which in turn drives metastatic dissemination and resistance to immunotherapy. A deeper understanding of these programs may provide novel opportunities to enhance the efficacy of existing immunotherapies.
摘要
免疫疗法已经彻底改变了癌症治疗方法，但大多数患者没有响应。虽然肿瘤抗原是有效免疫疗法所必需的，但有利的肿瘤免疫微环境也是至关重要的。在这篇综述中，我们讨论了新出现的证据，即肿瘤细胞利用细胞可塑性和去分化程序来逃避免疫监视，这反过来又推动了转移扩散和对免疫疗法的耐药性。对这些程序的更深入了解可能为增强现有免疫疗法的疗效提供新的机会。
相似文献
1
How Tumor Cell Dedifferentiation Drives Immune Evasion and Resistance to Immunotherapy.肿瘤细胞去分化如何驱动免疫逃逸和对免疫治疗的抵抗。
Cancer Res. 2020 Oct 1;80(19):4037-4041. doi: 10.1158/0008-5472.CAN-20-1420. Epub 2020 Jun 18.
2
Acquired resistance to cancer immunotherapy.获得性癌症免疫疗法耐药性。
Semin Immunopathol. 2019 Jan;41(1):31-40. doi: 10.1007/s00281-018-0692-y. Epub 2018 Jul 2.
3
The Role of mRNA Translational Control in Tumor Immune Escape and Immunotherapy Resistance.mRNA 翻译控制在肿瘤免疫逃逸和免疫治疗耐药中的作用。
Cancer Res. 2021 Nov 15;81(22):5596-5604. doi: 10.1158/0008-5472.CAN-21-1466. Epub 2021 Sep 1.
4
Emerging role of metabolic reprogramming in tumor immune evasion and immunotherapy.代谢重编程在肿瘤免疫逃逸和免疫治疗中的新作用。
Sci China Life Sci. 2021 Apr;64(4):534-547. doi: 10.1007/s11427-019-1735-4. Epub 2020 Aug 17.
5
Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion.EMT 与 PD-L1 信号转导之间的通讯：肿瘤免疫逃逸的新见解。
Cancer Lett. 2020 Jan 1;468:72-81. doi: 10.1016/j.canlet.2019.10.013. Epub 2019 Oct 9.
6
Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion.铁死亡在癌症获得性耐药和免疫逃逸的十字路口。
Nat Rev Cancer. 2019 Jul;19(7):405-414. doi: 10.1038/s41568-019-0149-1.
7
Fibroblasts Fuel Immune Escape in the Tumor Microenvironment.成纤维细胞助力肿瘤微环境中的免疫逃逸。
Trends Cancer. 2019 Nov;5(11):704-723. doi: 10.1016/j.trecan.2019.09.009. Epub 2019 Oct 29.
8
Metabolic Regulation of Tregs in Cancer: Opportunities for Immunotherapy.癌症中调节性T细胞的代谢调控：免疫治疗的机遇
Trends Cancer. 2017 Aug;3(8):583-592. doi: 10.1016/j.trecan.2017.06.005. Epub 2017 Jul 14.
9
Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes.抗血管生成药物——克服肿瘤内皮细胞不应答和改善免疫治疗效果。
Nat Rev Clin Oncol. 2021 Aug;18(8):527-540. doi: 10.1038/s41571-021-00496-y. Epub 2021 Apr 8.
10
Targeting Autophagy in the Tumor Microenvironment: New Challenges and Opportunities for Regulating Tumor Immunity.靶向肿瘤微环境中的自噬：调控肿瘤免疫的新挑战和新机遇。
Front Immunol. 2018 Apr 25;9:887. doi: 10.3389/fimmu.2018.00887. eCollection 2018.
引用本文的文献
1
Unveiling the heterogeneity and immunotherapy potency of tumor-associated neutrophils in the tumor microenvironment of gastric cancer.揭示胃癌肿瘤微环境中肿瘤相关中性粒细胞的异质性和免疫治疗潜力。
BMC Gastroenterol. 2025 Apr 28;25(1):303. doi: 10.1186/s12876-025-03920-0.
2
DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures.DLK1可区分具有不同分子特征的1型神经纤维瘤病相关恶性外周神经鞘瘤亚型。
Clin Cancer Res. 2025 May 15;31(10):1988-2009. doi: 10.1158/1078-0432.CCR-24-3029.
3
ITGB1/FERMT1 mechanoactivation enhances CD44 characteristic stemness in oral squamous cell carcinoma via ubiquitin-dependent CK1α degradation.整合素β1/踝蛋白1机械激活通过泛素依赖性细胞周期蛋白依赖性激酶1α降解增强口腔鳞状细胞癌中CD44的特征干性。
Oncogene. 2025 Jun;44(20):1530-1544. doi: 10.1038/s41388-025-03317-z. Epub 2025 Mar 5.
4
Exploring thymic stromal lymphopoietin in the breast cancer microenvironment: A preliminary study.探索乳腺癌微环境中的胸腺基质淋巴细胞生成素：一项初步研究。
Oncol Lett. 2025 Feb 13;29(4):182. doi: 10.3892/ol.2025.14928. eCollection 2025 Apr.
5
Role and value of the tumor microenvironment in the progression and treatment resistance of gastric cancer (Review).肿瘤微环境在胃癌进展和治疗抵抗中的作用和价值（综述）。
Oncol Rep. 2025 Jan;53(1). doi: 10.3892/or.2024.8847. Epub 2024 Nov 29.
6
The molecular features of lung cancer stem cells in dedifferentiation process-driven epigenetic alterations.去分化过程驱动的表观遗传改变中肺癌干细胞的分子特征。
J Biol Chem. 2024 Dec;300(12):107994. doi: 10.1016/j.jbc.2024.107994. Epub 2024 Nov 14.
7
The immunological and prognostic significance of the diabetes mellitus-related gene WFS1 in endometrial cancer.糖尿病相关基因 WFS1 在子宫内膜癌中的免疫和预后意义。
Front Immunol. 2024 Oct 16;15:1464421. doi: 10.3389/fimmu.2024.1464421. eCollection 2024.
8
Inferring cell differentiation maps from lineage tracing data.从谱系追踪数据推断细胞分化图谱。
bioRxiv. 2024 Sep 13:2024.09.09.611835. doi: 10.1101/2024.09.09.611835.
9
Devil in the Dedifferentiated Details: A Rare Case of Primary Pulmonary Dedifferentiated Liposarcoma.去分化细节中的“恶魔”：一例罕见的原发性肺去分化脂肪肉瘤病例
Cureus. 2024 Aug 9;16(8):e66540. doi: 10.7759/cureus.66540. eCollection 2024 Aug.
10
Beta cell dedifferentiation in type 1 diabetes: sacrificing function for survival?1 型糖尿病中的β细胞去分化：为生存牺牲功能？
Front Endocrinol (Lausanne). 2024 Jun 6;15:1427723. doi: 10.3389/fendo.2024.1427723. eCollection 2024.
本文引用的文献
1
L1CAM defines the regenerative origin of metastasis-initiating cells in colorectal cancer.L1CAM 定义了结直肠癌细胞转移起始细胞的再生起源。
Nat Cancer. 2020 Jan;1(1):28-45. doi: 10.1038/s43018-019-0006-x. Epub 2020 Jan 13.
2
Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy.多模型临床前平台预测黑色素瘤对免疫治疗的临床反应。
Nat Med. 2020 May;26(5):781-791. doi: 10.1038/s41591-020-0818-3. Epub 2020 Apr 13.
3
Cell Intrinsic and Systemic Metabolism in Tumor Immunity and Immunotherapy.肿瘤免疫与免疫治疗中的细胞内在代谢和全身代谢
Cancers (Basel). 2020 Apr 1;12(4):852. doi: 10.3390/cancers12040852.
4
Regenerative lineages and immune-mediated pruning in lung cancer metastasis.肺癌转移中的再生谱系和免疫介导的修剪。
Nat Med. 2020 Feb;26(2):259-269. doi: 10.1038/s41591-019-0750-6. Epub 2020 Feb 10.
5
Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1.通过靶向鞘氨醇激酶-1 克服黑色素瘤对免疫检查点抑制剂的耐药性。
Nat Commun. 2020 Jan 23;11(1):437. doi: 10.1038/s41467-019-14218-7.
6
MYC Instructs and Maintains Pancreatic Adenocarcinoma Phenotype.MYC 指导并维持胰腺导管腺癌的表型。
Cancer Discov. 2020 Apr;10(4):588-607. doi: 10.1158/2159-8290.CD-19-0435. Epub 2020 Jan 15.
7
Tumor Immunology and Tumor Evolution: Intertwined Histories.肿瘤免疫学和肿瘤进化：交织的历史。
Immunity. 2020 Jan 14;52(1):55-81. doi: 10.1016/j.immuni.2019.12.018.
8
Epigenetic CRISPR Screen Identifies as an Immunotherapeutic Target in -Mutant Lung Adenocarcinoma.表观遗传 CRISPR 筛选鉴定 为 - 突变型肺腺癌的免疫治疗靶点。
Cancer Discov. 2020 Feb;10(2):270-287. doi: 10.1158/2159-8290.CD-19-0780. Epub 2019 Nov 19.
9
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.临床 KRAS(G12C) 抑制剂 AMG 510 可引发抗肿瘤免疫。
Nature. 2019 Nov;575(7781):217-223. doi: 10.1038/s41586-019-1694-1. Epub 2019 Oct 30.
10
The great escape: tumour cell plasticity in resistance to targeted therapy.肿瘤细胞的“大逃亡”：靶向治疗耐药中的可塑性。
Nat Rev Drug Discov. 2020 Jan;19(1):39-56. doi: 10.1038/s41573-019-0044-1. Epub 2019 Oct 10.
Zotero 插件